Skip to content

Application of esketamine in the painless gastroscopy: a randomized controlled trial

Application of esketamine in the painless gastroscopy: a randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047033
Enrollment
Unknown
Registered
2021-06-07
Start date
2021-06-07
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outpatient anesthesia

Interventions

Control group:1.5mg/kg propofol+0.1µg/kgsufentanil
Experimental group1:0.2mg/kg esketamine+1.5mg/kg propofol
Experimental group2:0.3mg/kg esketamine+1.5mg/kg propofol
Experimental group3:0.4mg/kg esketamine+1.5mg/kg propofol

Sponsors

Department of Anesthesiology, The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years; 2. EVL, EVHT, EVS, patients who clearly have gastric polyps and need digestive endoscopy; 3. ASA I-III level; 4. 18.5 <= Body mass index (BMI)<= 28; 5. Agree to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who are intolerant to esketamine, ketamine hydrochloride, propofol, rocuronium, opioids and other drugs; 2. Patients who have used anesthetics within 24 hours or have used anesthetics within 15 days; 3. Poorly controlled or untreated hypertension (arterial hypertension-systolic/diastolic blood pressure exceeds 180/100 mmHg at rest); 4. Child liver function grade 3 or above before operation; 5. A history of severe cardiovascular disease (such as myocardial ischemia, heart failure, and arrhythmia, etc.); 6. Angina pectoris (unstable angina) caused by insufficient blood supply to the coronary blood vessels, or myocardial infarction occurred within the last 6 months patient; 7. Patients with craniocerebral injury, possible intracranial hypertension, cerebral aneurysm, cerebrovascular accident, and central nervous system disease; 8. Patients with hyperthyroidism; 9. Pregnant or lactating women; 10. Increased intraocular pressure (glaucoma) or puncture eye injury; 11. A history of drug and/or alcohol abuse within 3 months; 12. Patients with asthma; 13. Patients with mental system diseases (schizophrenia, mania, bipolar disorder, confusion, etc.), drug history and cognitive dysfunction; 14. Those who have participated in other drug trials three months before being selected; 15. The attending doctor or researcher believes that there are other situations that are not suitable for participating in this research.

Design outcomes

Secondary

MeasureTime frame
Propofol total dosage;Mental status;Time of resuscitation;Score of resuscitation;Secretion volume;

Primary

MeasureTime frame
Blood pressure;Heart rate;Pulse oxygen saturation;respiratory rate;

Countries

China

Contacts

Public ContactDan Ling

Department of Anesthesiology, The Second Affiliated Hospital of Chongqing Medical University

danling1@sohu.com+86 13983072922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026